Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$140,565 Mln
Revenue (TTM)
$23,820 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
5.6 %
P/E Ratio
38
P/B Ratio
2.8
Industry P/E
64.27
EV/EBITDA
21.7
Div. Yield
0.7 %
Debt to Equity
0.3
Book Value
$--
EPS
$5.1
Face value
--
Shares outstanding
715,670,016
CFO
$52,782.40 Mln
EBITDA
$59,034.30 Mln
Net Profit
$38,691.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Danaher (DHR)
| -15.9 | 3.4 | -7.1 | -27.7 | -4.7 | 6.5 | 12.7 |
|
BSE Sensex
| 4.3 | 3.9 | 7.7 | 10.3 | 14.5 | 21.5 | 11.4 |
|
S&P 100
| -1.1 | 13.0 | -4.3 | 14.0 | 17.7 | 16.4 | 11.9 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Danaher (DHR)
| -0.8 | -1.7 | -19.3 | 48.6 | 45.3 | 49.6 | 11.7 |
|
S&P 100
| 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 | -5.8 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Danaher (DHR)
|
193.2 | 140,564.8 | 23,820.0 | 3,765.0 | 20.4 | 7.4 | 38 | 2.8 |
| 134.2 | 235,835.3 | 42,344.0 | 13,502.0 | 19.0 | 30.5 | 17.6 | 4.8 | |
| 174.8 | 50,743.8 | 20,867.0 | 1,498.0 | 11.0 | 5.9 | 34.3 | 2.0 | |
| 105.8 | 157,798.1 | 17,553.0 | 2,032.0 | 16.0 | 9.5 | 77.9 | 7.1 | |
| 76.7 | 45,778.3 | 5,538.8 | 4,180.7 | 22.0 | 42.6 | 32.2 | 4.5 | |
| 510.1 | 41,666.6 | 3,931.8 | 895.0 | 29.5 | 58.4 | 47.8 | 28.8 | |
| 556.0 | 202,004.4 | 8,714.9 | 2,476.1 | 28.2 | 15 | 82.4 | 11.7 | |
| 248.2 | 37,148.0 | 5,021.5 | 1,313.3 | 31.8 | 24.5 | 28.4 | 6.7 | |
| 384.7 | 150,836.7 | 23,218.0 | 2,859.0 | 15.9 | 8.6 | 53.5 | 7.2 | |
| 407.0 | 156,252.3 | 42,898.0 | 6,515.0 | 18.5 | 13.2 | 24.3 | 3.1 |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments.... The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia. Address: 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701 Read more
Co-Founder & Chairman
Mr. Steven M. Rales
Co-Founder & Chairman
Mr. Steven M. Rales
Headquarters
Washington, DC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Danaher Corporation (DHR) stood at $ 85,761 Mln as on 31-Mar-25
The share price of Danaher Corporation (DHR) is $193.17 (NYSE) as of 21-May-2025 10:36 EDT. Danaher Corporation (DHR) has given a return of -4.7% in the last 3 years.
Danaher Corporation (DHR) has a market capitalisation of $ 140,565 Mln as on 20-May-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Danaher Corporation (DHR) is 2.76 times as on 20-May-2025, a 22% discount to its peers’ median range of 3.56 times.
The P/E ratio of Danaher Corporation (DHR) is 37.99 times as on 20-May-2025, a 41% discount to its peers’ median range of 64.27 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Danaher Corporation (DHR) and enter the required number of quantities and click on buy to purchase the shares of Danaher Corporation (DHR).
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia. Address: 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701
The CEO & director of Mr. Steven M. Rales. is Danaher Corporation (DHR), and CFO & Sr. VP is Mr. Steven M. Rales.
There is no promoter pledging in Danaher Corporation (DHR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
22,453
|
|
|
20,284
|
|
|
15,328
|
|
|
15,231
|
|
|
14,764
|
|
|
4,902
|
|
|
4,502
|
|
|
4,098
|
|
|
3,622
|
| Danaher Corporation (DHR) | Ratios |
|---|---|
|
Return on equity(%)
|
7.37
|
|
Operating margin(%)
|
20.39
|
|
Net Margin(%)
|
15.81
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Danaher Corporation (DHR) was $0 Mln.
$-4.61
(
